About this trial
This study focuses on both hospitalized and outpatient populations. Through a multicenter, retrospective study, it aims to comprehensively characterize:The comorbidity of interstitial lung diseases (ILD) and airway diseases;The comorbidity of ILD with other intrapulmonary diseases;The comorbidity of airway diseases with other intrapulmonary diseases;The comorbidity of ILD and airway diseases with extrapulmonary diseases.Based on these findings, the study seeks to propose classification and diagnostic criteria for ILD and airway disease comorbidities.Additionally, a multicenter, prospective, disease-specific cohort study will be conducted to observe the prognosis of patients with ILD and/or airway diseases, identify prognostic factors, and grade the severity of comorbid conditions based on these factors.Finally, the study will analyze the current state of interventions and the medical costs associated with ILD and airway disease comorbidities through a cost-effectiveness analysis, aiming to propose new strategies for integrated disease management.
Eligibility criteria
Qualifiers
age between 40-80 years old;
inpatients with an admission diagnosis of COPD, Idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, patients with the following diagnoses were screened by chest CT (slice thickness ≤1.5 mm) during hospitalization and by in-hospital or prior pulmonary function;
the inpatients could complete pulmonary function and chest CT examination within 1 month after discharge;
among outpatients, patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, COPD with pulmonary interstitial abnormalities, idiopathic pulmonary fibrosis with airway lesions, nonspecific interstitial pneumonia with airway lesions, pulmonary fibrosis with emphysema syndrome were diagnosed through chest CT (layer thickness ≤1.5mm) and lung function;
Disqualifiers
expected survival less than 12 months;
planned lung transplantation or pneumonectomy within 12 months;
pregnant or lactating women.
Trial design
Treatments tested in this trial
- no intervention
Treatment groups
7
Treatment groupsSee each treatment group below.
Locations
Sponsors and collaborators
Xiangya Hospital of Central South University
Lead sponsor
Beijing Hospital
Collaborator
Henan Provincial People's Hospital
Collaborator
Zhejiang University
Collaborator
Zhongshan Hospital (Xiamen), Fudan University
Collaborator
The Affiliated Hospital of Qingdao University
Collaborator
The Affiliated Hospital Of Guizhou Medical University
Collaborator
China-Japan Friendship Hospital
Collaborator
First Hospital of China Medical University
Collaborator